In the article, “An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples”, by Di Lorenzo et al. (Expert Opin Pharmacother 2011;12(10):1491-1497), an error has been identified. In the Abstract, the sentence, “After adjusted matching, the estimated median OS benefit is 32.7 weeks (95% CI: 22, 64) and 81.5 weeks (95% CI: 78, 86) for sorafenib and everolimus patients, respectively”, should read, “After adjusted matching, the estimated median OS benefit is 32.0 weeks (95% CI: 22, 64) and 81.5 weeks (95% CI: 78, 86) for sorafenib and everolimus patients, respectively.” In the Results section, the sentence, “Overall, the everolimus data resulted in a clinically meaningful increase in median OS relative to the sorafenib data, with median OS estimates of 81.5 weeks (95% CI: 78, 86) for the everolimus population and 32.7 weeks (95% CI: 22, 64) for the sorafenib population (Table 2)”, should read, “Overall, the everolimus data resulted in a clinically meaningful increase in median OS relative to the sorafenib data, with median OS estimates of 81.5 weeks (95% CI: 78, 86) for the everolimus population and 32.0 weeks (95% CI: 22, 64) for the sorafenib population (Table 2).”
Informa Healthcare and the authors of this article would like to apologize for any confusion caused.